High capacity homogeneous non-radioactive cortisol detection assays for human 11β-hydroxysteroid dehydrogenase type 1

Assay and Drug Development Technologies

Volumn 5, Issue 1, 2007, Pages 105-115

  Yu, Violeta ^a   Tudor, Yanyan ^a   Hale, Clarence ^a   Plant, Matthew ^a   Ki, Won Kim ^a   Wang, Minghan ^a   Nguyen, Yen ^a   San Miguel, Tisha ^a   Chen, Michelle ^a   Nybo, Rebecca ^a   Baumgartner, Jamie ^a   Kurzeja, Robert J M ^a   Powers, David ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; HYDROCORTISONE;

ARTICLE; ASSAY; CHEMOLUMINESCENCE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HORMONE DETERMINATION; HUMAN; MICHAELIS CONSTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; VALIDATION PROCESS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; CHEMILUMINESCENT MEASUREMENTS; ELECTROCHEMISTRY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HYDROCORTISONE; MICROCHEMISTRY; RADIOISOTOPE DILUTION TECHNIQUE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 34147193503     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2006.047     Document Type: Article

References (22)

1. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; for the Conference participants: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109:433-438.
2. DeFronzo RA, Ferrannini E: Insulin resistance. A multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
3. Wang M: The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome. Nutr Metab 2005;2:3.
4. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, et al.: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin En docrinol Metab 2003;88:5593-5602.
5. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
6. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, et al.: Metabolic syndrome without obesity: hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004;101:7088-7093.
7. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al.: 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94:14924-14929.
8. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al.: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-938.
9. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR: Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276:41293-41300.
10. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, et al.: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45: 1528-1532.
11. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, et al.: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144:4755-4762.
12. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, et al.: 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202:517-527.
13. Walker EA, Clark AM, Herwison M, Ride JP, Steward PM: Functional expression, characterization, and purification of the catalytic domain of human 11 beta-hydroxysteroid dehydrogenase type 1. J Biol Chem 2001;276:21343-21350.
14. Blum A, Martin HJ, Maser E: Human 11beta-hydroxysteroid dehydrogenase 1/carbonyl reductase: recombinant expression in the yeast Pichia pastoris and Escherichia coli. Toxicology 2000;144:113-120.
15. Draper N, Stewart PM: 11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 2005;186:251-271.
16. Solly K, Mundt SS, Zokian HJ, Ding GJ, Hermanowski-Vosatka A, Stralovici B, et al.: High-throughput screening of 11β-hydroxysteroid dehydrogenase type 1 in scintillation proximity assay format. Assay Drug Dev Technol 2005;3:377-384.
17. Mundt S, Solly K, Thieringer R, Hermanowski-Vosatka A: Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Assay Drug Dev Technol 2005;3:367-375.
18. Kim KW, Wang Z, Busby J, Tsuruda T, Chen M, Hale C, et al.: The role of tyrosine 177 in human 11 beta-hydroxysteroid dehydrogenase type 1 in substrate and inhibitor binding: an unlikely hydrogen bond donor for the substrate. Biochim Biophys Acta 2006;1764:824-830.
19. Cheng Y, Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
20. Ozols J: Lumenal orientation and post-translational modification of the liver microsomal 11 beta-hydroxysteroid dehydrogenase. J Biol Chem 1995;270:2305-2312.
21. Blum A, Martine HJ, Maser E: Human 11β-hydroxysteroid dehydrogenase type 1 is enzymatically active in its non-glycosylated form. Biochem Biophys Res Commun 2000; 276:428-434.
22. Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RAS, Frey FJ, et al.: Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 2005;35:89-101.